Re: New S-A article
That's provided that I live long enough, this has certainly been a marathon, not a sprint. I believe the key is IMGN maintaining at least some degree of ownership in products they're developing. I can understand monetizing to get operational funds, but in SGEN's case they smartly issued more stock when the price was high, IMGN has diluted less, but often at lower prices. I would much prefer dilution to selling off all of IMGN853 for a small royalty stream, they indicated wanting a ROW partnership, I think they should stick to their guns.
It's ironic that SGEN's most advanced new product was acquired from someone else and works with Kadcyla, which we no longer receive anything for. Our greatest success to date is helping to build SGEN's bottom line.
I hope that ASH is positive, and I plan to check with my Dr. if he's attending. I won't see him before, but we exchange emails routinely.